NEW YORK, March 14, 2017 -- Hanweck, a leading provider of real-time risk analytics on global derivatives markets, today announced that Jean-Jacques Louis, Senior Vice President of Corporate Strategy at Nasdaq, has joined its Board of Directors. At Nasdaq, Mr. Louis is responsible for the strategic and financial analyses and execution of all corporate and business unit investments. Nasdaq is a strategic investor in Hanweck.
“I am pleased to welcome Jean-Jacques Louis to the Hanweck Board,” said Gerald A. Hanweck Jr., PhD, Founder and CEO of Hanweck. “His experience at Nasdaq, a leader in the listed markets and in financial technology, will add significant value to our firm. Moreover, we will benefit from Jean-Jacques’ deep knowledge and expertise in corporate structure and finance as we continue our rapid growth trajectory.”
Mr. Louis added, “I am thrilled to join the board of Hanweck to help support its growth plans alongside its distinguished directors. Jerry and his team’s deep expertise in real-time risk analytics are second to none. The marquee customer list and relationships they have built over time is quite impressive and bodes well for its future growth. Hanweck tools and solutions have become critical components to the infrastructure and workflow processes of their clients.”
Mr. Louis has been a financial professional in the capital markets and investment banking industries since 1992. Prior to joining Nasdaq in 2004, he was an M&A banker with UBS Investment bank in its Financial Institutions Group. In this role, Mr. Louis provided counsel and executed a number of US and international transactions in the financial institutions, financial technology and broker-dealer industries.
He began his career with Viel Tradition where he led the development of the short-term interest rate derivatives desk (interest rate swaps, forward rate agreements, swaptions, cap/floor). Viel Tradition is one of the largest interbank dealers in the world. Mr. Louis received a Master of Science in Management from the Reims School of Management in Reims, France and an MBA from Dartmouth's Tuck School of Business in Hanover, NH.
About Hanweck
Hanweck is the leading provider of real-time risk analytics on global derivatives markets focusing on the large-scale risk problems of banks, broker/dealers, hedge funds, central counterparties and exchanges -- where the number of instruments and positions number in the millions. Hanweck delivers its risk analytics as a real-time service -- usually in the form of a data feed -- thereby dramatically simplifying integration with its customers' risk architecture. Hanweck's institutional investors include Nasdaq and Argentum, a New York-based private equity firm. For more information, please visit www.hanweck.com or follow Hanweck on Twitter and LinkedIn.
Contact Information Media/Marketing: Molly McGregor, [email protected] Sales/Business Development: [email protected]


Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Grok AI Controversy on X Sparks Global Outrage Over Nonconsensual Images
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 



